TriangleInvestigator Choice Immunotherapy… (NCT07603856)
Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab) trial for Non-Small Cell Lung Cancer (NCT07603856). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with metastatic or recurrent non-small-cell lung cancer progressing after one qualifying PD1/PD-L1 treatment line. EGFR, ALK, ROS1, RET, NTRK, and HER2 drivers exclude entry; BRAF, KRAS, or MET drivers require prior targeted treatment.
The idea: random assignment compares focused radiation plus checkpoint immunotherapy against chemotherapy. Doctors select the drugs. At least one tumor must be suitable for ablative radiation. Researchers test disease control through progression-free survival after prior immunotherapy has failed.
This phase 2 study plans 39 patients. The University of Chicago sponsors the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.